Industry Reports
CTI BioPharma Announces $15.7 Million Registered Direct Offering
CTI BioPharma Corp. announced that it has entered into an agreement with institutional investors to purchase 10 million shares of the Company's common stock in a registered direct offering conducted without an underwriter or placement agent for gross proceeds...
Industry Reports
Seattle Genetics, BMS to evaluate Adcetris and Opdivo combination
Seattle Genetics and Bristol-Myers Squibb (BMS) have entered into a clinical trial collaboration agreement to evaluate the investigational combination of Adcetris and Opdivo in two planned Phase I/II clinical trials. Adcetris (brentuximab vedotin) is Seattle Genetics'...
Industry Reports
Ireland’s Shire to acquire NPS Pharmaceuticals for $5.2bn
Irish drugmaker Shire has signed a merger agreement to acquire US-based NPS Pharmaceuticals for $5.2bn. As part of the deal, Shire will acquire NPS Pharma's outstanding shares for $46 per share in cash. The transaction was...
Industry Reports
Pfizer acquires Baxter’s marketed vaccines portfolio for $635m
US-based drug maker Pfizer has completed the acquisition of marketed vaccines portfolio from Baxter International for $635m. As part of the deal, Pfizer also acquired a portion of Baxter's facility in Orth, Austria, where these vaccines...
Industry Reports
Johnson & Johnson completes acquisition of AliosBioPharma for $1.75bn
US-based Johnson & Johnson (J&J) has completed the acquisition of a privately held clinical stage biopharmaceutical company, AliosBioPharma, for $1.75bn in cash. Based in California, US, AliosBioPharma develops therapies for the treatment of viral diseases. The...
Industry Reports
Aegerion to acquire AstraZeneca’s lipodystrophy treatment Myalept for $325m
Aegerion Pharmaceuticals has signed an agreement to acquire an orphan product Myalept (metreleptin for injection) from AstraZeneca. AstraZeneca will receive $325m upfront payment to divest the rights to develop, manufacture and commercialise Myalept, subject to an...
Industry Reports
Johnson & Johnson Reports 2014 Second-Quarter Results
Sales of $19.5 Billion increased 9.1% Versus 2013 Second Quarter; Second-Quarter EPS was $1.51 Excluding Special Items, 2014 Second-Quarter EPS of $1.66 increased 12.2%* Johnson & Johnson today announced sales of $19.5 billion for the second...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
